Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
6(75%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
1
13%
Ph phase_3
5
63%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

8

all time

Status Distribution
Active(6)
Completed(2)

Detailed Status

Recruiting6
Completed2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 35 (62.5%)

Trials by Status

recruiting675%
completed225%

Recent Activity

6 active trials
Showing 5 of 8
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011
recruitingphase_3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07321886Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Recruiting
NCT07392190Phase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Recruiting
NCT07369011Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
NCT07353931Phase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Recruiting
NCT07282600Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Recruiting
NCT07215559Phase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Recruiting
NCT06916065Phase 1

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Completed
NCT06916091Phase 1

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8